drugset / Trial / NCT00648362

Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

NCT00648362

Phase 1 Completed 40 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's glimepiride 1 mg tablets to Aventis Amaryl® 1 mg tablets following a single, oral 1 mg (1 x 1 mg) dose administered under fasting conditions.

Timeline

Start
2004-11
Primary completion
2004-11
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 1 mg Oral

Indications

No indication recorded.